Penny Markham

Executive Vice President, Liver Cirrhosis R&D at BioVie Inc.
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Clifton, Virginia, United States, US

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Experience

  • BioVie Inc.
    • United States
    • Biotechnology
    • 1 - 100 Employee
    • Executive Vice President, Liver Cirrhosis R&D
      • Sep 2021 - Present

    • Chief Scientist Officer
      • Aug 2018 - Aug 2021

    • Chief Scientist
      • Jan 2015 - Jul 2018

  • PharmaIN, Corp.
    • Independent Consultant
      • 2004 - 2018

      Modified formulation of GLP-1 for Type 1 diabetes Novel formulation of lysostaphin for systemic delivery to treat MRSA infections Terlipressin analogues for delivery subQ

  • Recursion Pharmaceuticals
    • Independent Consultant
      • 2014 - 2016

      Assisted in securing initial $1MIL in non-dilutive funding for novel screening platform to identify treatments for orphan drugs legitimizing approach for investors and pharmaceutical companies.

  • LAT Pharma
    • Independent Consultant
      • 2009 - 2016

      Development of terlipressin analogues for subQ injection; preclinical studies; non-dilutive funding; obtained Orphan Designation

  • Impax Laboratories
    • Independent Consultant
      • 2012 - 2014

      Provided supportive rationale for the development of reformulated drugs for numerous diverse CNS indications including comparative analysis of efficacy and safety parameters, patient pool estimates, Orphan Drug designation, benchmarking and KOL analysis.

  • VenatoRx Pharmaceuticals, Inc.
    • Independent Consultant
      • 2012 - 2012

      Malvern, PA Consulted on NIH Biodefense BAA for $20 MIL (awarded) External advisory committee for B-lactamase inhibitors

  • Protez Pharmaceuticals
    • Independent Consultant
      • 2006 - 2011

      Research and grant strategy for novel antimicrobial treatments for MDR bacterial infections, biodefense bacterial pathogens and biofilms.

  • Protez Pharmaceuticals
    • Head, Research Biology
      • 2003 - 2005

      Greater Chicago Area

  • Illinois Technology Enterprise Center ITEC
    • Independent Consultant
      • 2002 - 2004

      Greater Chicago Area Consulted on non-dilutive funding strategies for emerging start-up pharmaceutical companies.

  • Influx Inc
    • Co-Founder and Director of Research
      • 1997 - 2003

      Greater Chicago Area As Co-founder and Director of Research: initiated 5 programs in discovery and early development of novel potentiators of antimicrobials; secured $5 MIL in non-dilutive grant funding; served as Principal Investigator on eight NIH grants; managed 5 Ph.D level researchers.

Community

You need to have a working account to view this content. Click here to join now